Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

摘要: Neoadjuvant chemotherapy (NACT) prior to liver resection is advantageous for patients with colorectal cancer metastases (CLM). Bevacizumab- or cetuximab-based NACT may affect patient outcome and curative rate, but comparative studies on differential tumour regression grade (TRG) associated distinct antibodies-associated regimens are lacking. Ninety-three consecutive received plus bevacizumab (n = 46) cetuximab 47) followed by CLM resection. Pathological response was determined in each resected metastasis as TRG rated from 1 (complete) 5 (no response). Except KRAS mutations prevailing versus (57 vs. 21 %, p 0.001), characteristics were well balanced. Median follow-up 31 months (IQR 17–48). Bevacizumab induced significantly better pathological rates (TRG1–3: 78 34 < 0.001) complete responses (TRG1: 13 0 0.012) respect cetuximab. Three-year progression-free survival (PFS) overall (OS) not different the two cohorts. At multivariable analysis, significant association found number of (p 0.015) allocation while mutation showed only a trend. Significant poorer PFS OS low grades 0.009 0.001, respectively), R2 presence extrahepatic disease (both 0.007 respectively). Bevacizumab-based regimens, although influenced status, improve if compared NACT. Possible impact among has still be elucidated.